Mortality Due to COVID-19 in the COVID-AGEBRU Study

Covid19 Clinical Trial

— COVID-AGEBRU  

Official title:

Predictors of Intrahospital Mortality in Older Patients Admitted Due to COVID-19 in the COVID-19 AGEBRU Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04756479
• Other study ID #: COVID-19 AGE-BRUGMANN 2020/111
• Status: Completed
• Start date: March 1, 2020
• Est. completion date: June 30, 2020

Study information

• Verified date: March 2022
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The COVID-Age Brugmann study aims to identify the clinical predictors of mortality risk in older patients admitted to an acute care unit due to COVID-19

Description:

The COVID-19 disease has been shown to be associated to higher mortality risk and health adverse consequences. Despite of the fact that the SAR-COV2 virus has been shown that affects every populations, the negative impact is higher in older people, pointing this population as the most severely affected.

The COVID-Age Brugmann study aims to identify if comorbidity, geriatric syndromes, and health issues at admission are associated to mortality risk in older patients admitted to an acute care unit due to COVID-19

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: June 30, 2020
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 70 and older

• Patients admitted to an acute care geriatric unit due to COVID-19

• Patients with COVID-19 by PCR, serology or CT scan suggestive of this disease

Exclusion Criteria:

• No other demographic or clinical exclusion criteria will be applied

Related Conditions & MeSH terms

• COVID-19
• Covid19
• Frailty
• Morbidity, Multiple
• Old Age; Debility

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Brugmann University Hospital

Country where clinical trial is conducted

Belgium, 

References & Publications (3)

Ménager P, Brière O, Gautier J, Riou J, Sacco G, Brangier A, Annweiler C, Geria-Covid Study Group OBOT. Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. Nutrients. 2020 Dec 24;13(1). pii: E39. doi: 10.3390/nu13010039. — View Citation

Mendes A, Serratrice C, Herrmann FR, Genton L, Périvier S, Scheffler M, Fassier T, Huber P, Jacques MC, Prendki V, Roux X, Di Silvestro K, Trombert V, Harbarth S, Gold G, Graf CE, Zekry D. Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study. J Am Med Dir Assoc. 2020 Nov;21(11):1546-1554.e3. doi: 10.1016/j.jamda.2020.09.014. Epub 2020 Sep 15. — View Citation

Miralles O, Sanchez-Rodriguez D, Marco E, Annweiler C, Baztan A, Betancor É, Cambra A, Cesari M, Fontecha BJ, Gasowski J, Gillain S, Hope S, Phillips K, Piotrowicz K, Piro N, Sacco G, Saporiti E, Surquin M, Vall-Llosera E. Unmet needs, health policies, and actions during the COVID-19 pandemic: a report from six European countries. Eur Geriatr Med. 2021 Feb;12(1):193-204. doi: 10.1007/s41999-020-00415-x. Epub 2020 Oct 15. Review. Erratum in: Eur Geriatr Med. 2021 Jun;12(3):667. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality during hospital admission (admission up to discharge time)	Vital status was obtained from medical records	Through study completion, an average of one month.
Secondary	Prevalence of medical diseases and geriatric syndromes	Clinical and demographical conditions, and geriatric syndromes	Through study completion, an average of one month.